|  |  | 

India Top Headlines

Eye on Health Security: Fillip for API, Medical Device Production | India News


NEW DELHI: Boosting local production of high-end API drugs and medical devices, the government on Monday published guidelines for four incentive schemes for the development of bulk drug and medical device parks across the country .
The production-linked incentive plans were approved by the Cabinet in March and are worth more than Rs 10 billion.
The schemes aim to reduce India’s dependence on China for raw materials to produce crucial antibiotics, HIV drugs, vitamins and cardiovascular drugs, and in the production of medical devices, on which India is critically dependent on imports.
“In line with Prime Minister Narendra Modi’s vision, the schemes have been conceptualized to turn India Atma Nirbhar into the pharmaceutical sector,” said Union Minister for Chemicals and Fertilizers DV Sadananda Gowda.
The scheme is primarily concerned with the production of 53 Critical Active Pharmaceutical Ingredients (API) or Key Starting Materials (KSM).
The coronavirus crisis has exposed weakness in global supply chains and has posed a threat to the country’s health security, Gowda said.
While the proactive steps of the Department of Pharmaceutical Products and the National Pharmaceutical Pricing Authority ensured a constant supply of medicines and prevented any shortages even during the shutdown, it was felt that domestic capabilities in the production of APIs and medical devices have to be increased to to be able to eliminate any risk to health safety, he added.
“The details of the schemes have been meticulously worked out after extensive consultation with stakeholders, including industries and state governments. The selection of their location will be based on objective criteria and in a spirit of competitive federalism,” said Gowda. .
Similarly, eligible manufacturers will be selected for the PLI scheme based on the ratings obtained on the evaluation criteria according to the guidelines, he added.
“With the support of the central and state governments, these parks will be based on a plug and play model with prior regulatory approvals, state-of-the-art infrastructure, excellent connectivity, affordable land, competitive service rates, and a strong R&D ecosystem, etc. . ” Gowda said.
“I am sure that these schemes will get a good response from interested companies. These parks will be able to attract significant investment and the latest technology. Once they are operational, in two or three years, these parks will generate thousands of direct and indirect jobs. ., reduce dependence on imports and make India a global pharmaceutical hub, “said Gowda.
The idea is also to consolidate India’s position as a global provider of medicines. As is already known, despite various possibilities, India has supplied critical drugs such as hydroxychloroquine and paracetamol to several countries, he added.

Times of India